Aryl carbonyl derivatives as therapeutic agents

1. A compound of Formula (Ib)

wherein

R 24 is selected from the group consisting of F, Cl, Br, and —CH 3 ;

L 1 is —C(O)—;

G 1 is selected from the group consisting of methyl, ethyl, propyl, butyl, isopropyl, isobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, piperidyl, and hexahydroazepinyl; L 2 is —N—(R 20 )—; R 20 is H;

L 3 is —C(O)—;

R 1 is hydrogen;

G 2 is

R 43 is —C 1-6 -alkylene-C(O)OR 54 ;

R 54 is hydrogen, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, 2-pentyl, or 3-methyl-butyl;

or a pharmaceutically acceptable salt or solvate thereof.

2. The compound, pharmaceutically acceptable salt or solvate thereof of claim 1 , wherein G 1 is cyclopentyl.

3. The compound, pharmaceutically acceptable salt or solvate thereof of claim 1 , wherein R 24 is methyl.

4. The compound, pharmaceutically acceptable salt or solvate thereof of claim 2 , wherein R 24 is methyl.

5. The compound, pharmaceutically acceptable salt or solvate thereof of claim 1 , wherein R 54 is hydrogen.

6. The compound, pharmaceutically acceptable salt or solvate thereof of claim 2 , wherein R 54 is hydrogen.

7. The compound, pharmaceutically acceptable salt or solvate thereof of claim 3 , wherein R 54 is hydrogen.

8. The compound, pharmaceutically acceptable salt or solvate thereof of claim 4 , wherein R 54 is hydrogen.

9. The compound, pharmaceutically acceptable salt or solvate thereof of claim 1 , wherein R 43 is —CH 2 —C(O)OR 54 .

10. The compound of claim 1 , wherein the compound is selected from the group consisting of;

{2-[3-(2-Cyclopentanecarbonyl-4-methyl-phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester;

{2-[3-(2-Cyclopentanecarbonyl-4-methyl-phenyl)-ureido]-thiazol-4-yl} acetic acid;

2-[3-(2-Cyclopentanecarbonyl-4-methylphenyl)-ureido]-thiazole-4-carboxylic acid ethyl ester;

2-[3-(2-Cyclopentanecarbonyl-4-methylphenyl)-ureido]-thiazole-4-carboxylic acid;

{2-[3-(4-Methyl-2-[2-methylpropoxy] phenyl)-ureido]-thiazol-4-yl}-acetic acid;

{2-[3-(4-Bromo-2-cyclopentanecarbonyl-phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester;

{2-[3-(4-Bromo-2-cyclopentanecarbonyl-phenyl)-ureido]-thiazol-4-yl}-acetic acid;

3- {2-[3-(2-Cyclopentanecarbonyl-4-methyl-phenyl)-ureido]-thiazol-4-yl}-propionic acid ethyl ester;

3- {2-[3-(2-Cyclopentanecarbonyl-4-methyl-phenyl)-ureido]-thiazol-4-yl}-propionic acid;

{2-[3-(2-Cyclohexanecarbonyl-4-methyl-phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester;

{2-[3-(2-Cyclohexanecarbonyl-4-methyl-phenyl)-ureido]-thiazol-4-yl}-acetic;

{2-[3-(4-Chloro-2-cyclopentanecarbonyl-phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester;

{2-[3-(4-Chloro-2-cyclopentanecarbonyl-phenyl)-ureido]-thiazol-4-yl}-acetic acid;

{2-[3-(2-Cyclopentanecarbonyl-4-fluoro-phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; and

{2-[3-(2-Cyclopentanecarbonyl-4-fluoro-phenyl)-ureido]-thiazol-4-yl}-acetic acid or a pharmaceutically acceptable salt or solvate thereof.

11. The compound {2-[3-(2-cyclopentanecarbonyl-4-methyl-phenyl)-ureido]-thiazol-4-yl} acetic acid or a pharmaceutically acceptable salt or solvate thereof.

12. A pharmaceutical composition comprising the compound of Formula (Ib)

wherein

R 24 is selected from the group consisting of F, Cl, Br, and —CH 3 ;

L 1 is —C(O)—;

G 1 is selected from the group consisting of methyl, ethyl, propyl, butyl, isopropyl, isobutyl, cyclopentyl, cyclohexyl, tetrahydrofiaranyl, tetrahydropyranyl, piperidyl, and hexahydroazepinyl; L 2 is —N—(R 20 )—; R 20 is H;

L 3 is —C(O)—;

R 1 is hydrogen;

G 2 is

R 43 is —C 1-6 -alkylene-C(O)OR 54 ;

R 54 is hydrogen, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, 2-pentyl, or 3-methyl-butyl;

or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, diluent, excipient, or mixture thereof.

13. The pharmaceutical composition of claim 12 , wherein G 1 is cyclopentyl.

14. The pharmaceutical composition of claim 12 , wherein R 24 is methyl.

15. The pharmaceutical composition of claim 13 , wherein R 24 is methyl.

16. The pharmaceutical composition of claim 12 , wherein R 54 is hydrogen.

17. The pharmaceutical composition of claim 13 , wherein R 54 is hydrogen.

18. The pharmaceutical composition of claim 14 , wherein R 54 is hydrogen.

19. The pharmaceutical composition of claim 15 , wherein R 54 is hydrogen.

20. The pharmaceutical composition of claim 12 , wherein R 43 is —CH 2 —C(O)OR 54 .

21. The pharmaceutical composition of claim 12 , wherein the compound is selected from the group consisting of {2-[3-(2-Cyclopentanecarbonyl-4-methyl-phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester;

{2-[3-(2-Cyclopentanecarbonyl-4-methyl-phenyl)-ureido]-thiazol-4-yl} acetic acid;

2-[3-(2-Cyclopentanecarbonyl-4-methylphenyl)-ureido]-thiazole-4-carboxylic acid ethyl ester;

2 -[3-(2-Cyclopentanecarbonyl-4-methylphenyl)-ureido]-thiazole-4-carboxylic acid;

{2-[3-(4-Methyl-2-[ 2 -methylpropoxy] phenyl)-ureido]-thiazol-4-yl}-acetic acid;

{2-[3-( 4 -Bromo-2-cyclopentanecarbonyl-phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester;

{2-[3-(4-Bromo-2-cyclopentanecarbonyl-phenyl)-ureido]-thiazol-4-yl}-acetic acid;

3-{2-[3-(2-Cyclopentanecarbonyl-4-methyl-phenyl)-ureido]-thiazol-4-yl}-propionic acid ethyl ester;

3-{2-[3-(2-Cyclopentanecarbonyl-4-methyl-phenyl)-ureido]-thiazol-4-yl}-propionic acid;

{2-[3-(2-Cyclohexanecarbonyl-4-methyl-phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester;

{2-[3-(2-Cyclohexanecarbonyl-4-methyl-phenyl)-ureido]-thiazol-4-yl}-acetic;

{2-[3-(4-Chloro-2-cyclopentanecarbonyl-phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester;

{2-[3-(4-Chloro-2-cyclopentanecarbonyl-phenyl)-ureido]-thiazol-4-yl}-acetic acid;

{2-[3-(2-Cyclopentanecarbonyl-4-fluoro-phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; and

{2-[3-(2-Cyclopentanecarbonyl-4-fluoro-phenyl)-ureido]-thiazol-4-yl}-acetic acid, or a pharmaceutically acceptable salt or solvate thereof.

22. A pharmaceutical composition comprising the compound {2-[3-(2-cyclopentanecarbonyl-4-methyl-phenyl)-ureido]-thiazol-4-yl} acetic acid or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier, diluent, excipient, or mixture thereof.